Autres langues Center Laboratories, Inc.

Actions

4123

TW0004123005

Produits pharmaceutiques

Cours en clôture Taipei Exchange 30/09/2026			Varia. 5j.	Varia. 1 janv.
31,25 ^TWD	+0,81%		+0,81%	-21,13%

11/08	Center Laboratories, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
13/05	Center Laboratories annonce un bénéfice net de 1,97 milliard de TWD au premier trimestre	RE

Autres langues

11/08	Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
21/07	GenEditBio Limited announced that it has received TWD 550 million in funding from Center Laboratories, Inc.
13/05	Center Laboratories says Jan-Mar net profit at T$1.97 bln
13/05	Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
14/04	Center Laboratories, Inc. announces Annual dividend, payable on September 11, 2026
31/03	WuXi XDC Cayman Inc. completed the acquisition of 60% stake in BioDlink International Company Limited from a group of shareholders.
03/03	Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
14/01	WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion.
11/11	Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
13/08/25	Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
09/06/25	Tranche Update on Center Laboratories, Inc.'s Equity Buyback Plan announced on April 9, 2025.
09/06/25	Center Laboratories, Inc.'s Equity Buyback announced on April 9, 2025, has expired with 9,909,000 shares, representing 1.38% for TWD 383.08 million.
11/05/25	Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
08/05/25	Medeon Biodesign, Inc. cancelled the transaction announced on February 29, 2024
09/04/25	Center Laboratories, Inc. announces an Equity Buyback for 20,000,000 shares, representing 2.76% for TWD 9,141.18 million.
09/04/25	Center Laboratories, Inc. authorizes a Buyback Plan.
24/03/25	Guangzhou Hybot Technology Co., Ltd. announced that it has received CNY 450 million in funding from CS Capital Co., Ltd., Beijing Taiji Huaqing Peicheng Software Technology Co., Ltd., Hydrogenics Corporation, Guangzhou Shuimu Qingyun Equity Investment Partnership Enterprise (Limited Partnership), Beijing Shunyuan Changxin Consulting Management Partnership Enterprise (Limited Partnership, Hainan Yide Investment Partnership Enterprise (Limited Partnership), Center Laboratories, Inc.
14/03/25	Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
11/03/25	Center Laboratories, Inc. Proposes Dividend for Year Ended December 31, 2024
11/03/25	Center Laboratories, Inc. announced a financing transaction
27/02/25	Mycenax Biotech Inc. cancelled the transaction announced on March 13, 2024
14/11/24	Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
23/10/24	Shanghai Bao Pharmaceuticals Co., Ltd. announced that it has received CNY 425.748904 million in funding from Shanghai STCV Group, Shanghai Industrial Investment Co. Ltd., Investment Arm, Shanghai Shangshi Capital Management Co., Ltd., Shanghai Baoshan State Owned Capital Investment Management Co., Ltd., Center Laboratories, Inc.
25/09/24	Lumosa Therapeutics Co., Ltd. announced that it has received TWD 236.083275 million in funding from Center Laboratories, Inc.
13/08/24	Center Laboratories, Inc. Appoints Kuo-Lung Yen as Member of Remuneration Committee